IPSC — Century Therapeutics, Inc.
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 140
- Website: https://www.centurytx.com
Latest SEC filings for IPSC
- 8-K — 2026-10-02
- 3 — 2026-09-10
- 8-K — 2026-09-09
- 8-K — 2026-08-12
- 10-Q — 2026-08-12
- 8-K — 2026-06-16
- 8-K — 2026-06-12
- 8-K — 2026-06-08
- SCHEDULE 13G — 2026-05-15
- 10-Q — 2026-05-13
Latest IPSC news
- — Century Therapeutics (NASDAQ:IPSC) and BioStem Technologies (OTCMKTS:BSEM) Financial Analysis
- — Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
- — Century Therapeutics: Competitors May Be Quietly De-Risking Its Biggest Bet (seekingalpha.com)
Educational tool only — not investment advice.